Alnylam Pharmaceuticals (ALNY) Invested Capital (2009 - 2026)

Alnylam Pharmaceuticals has reported Invested Capital for 18 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 97.59% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 97.59% YoY), and the FY2025 full-year result was $789.2 million, up 390.51% from the prior year.
• Invested Capital for Q1 2026 stood at $1.1 billion, up from $789.2 million in the prior quarter.
• The five-year high for Invested Capital was $1.1 billion in Q1 2022, with the low at -$408.1 million in Q2 2023.
• Historically, Invested Capital has averaged $221.1 million across 5 years, with a median of $32.4 million in 2024.
• Annual changes were most pronounced in 2023 — Invested Capital sank 147.8% — and 2025, when it jumped 12209.26%.
• Alnylam Pharmaceuticals' Invested Capital stood at -$158.2 million in 2022, then slumped by 39.45% to -$220.6 million in 2023, then jumped by 172.92% to $160.9 million in 2024, then soared by 390.51% to $789.2 million in 2025, then jumped by 36.27% to $1.1 billion in 2026.
• The last three Invested Capital figures came in at $1.1 billion (Q1 2026), $789.2 million (Q4 2025), and $355.2 million (Q3 2025), per Business Quant data.